Bafna Pharmaceuticals Limited
NSE: BAFNAPH
NSE
72.00
-3.34 (-4.43%)
Prev Close
75.34
Open Price
71.57
Volume
1,466
Today Low / High
71.57 / 73
52 WK Low / High
69 / 104.8
Range
68 - 76
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 72, with a change of -3.34 (-4.43324%). The expected target range on the NSE is between 68 - 76. The stock is experiencing a downward trend on the NSE. Investors should be cautious as the price is currently declining.
09 May
71.57
0.60%
08 May
74.00
1.81%
07 May
75.00
-1.91%
06 May
75.00
0.00%
05 May
75.88
1.32%
02 May
81.00
-6.32%
30 Apr
80.49
-0.76%
29 Apr
76.51
4.52%
28 Apr
81.00
-1.22%
25 Apr
80.69
-0.36%
24 Apr
77.20
-0.36%
23 Apr
74.70
-0.91%
22 Apr
76.00
-0.13%
21 Apr
76.00
-3.68%
17 Apr
77.58
-3.53%
16 Apr
72.65
3.06%
15 Apr
74.00
1.18%
11 Apr
72.51
-0.01%
Bafna Pharmaceuticals Limited Graph
Bafna Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Bafna Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 72.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 72.00 | 72.72 | 65.45 - 79.99 |
| 73.44 | 58.75 - 88.13 | ||
| 74.16 | 51.91 - 96.41 | ||
| Bearish Scenario | 72.00 | 71.28 | 64.15 - 78.41 |
| 70.56 | 56.45 - 84.67 | ||
| 69.84 | 48.89 - 90.79 |
Overview of Bafna Pharmaceuticals Limited
ISIN
INE878I01022
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
2,763
Market Cap
1,703,253,600
Last Dividend
0
Official Website
IPO Date
2012-11-12
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of BAFNAPH
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2013-09-19 | September 19, 13 | 0.6 | 0.06 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 152.47 Cr | 107.25 Cr | 45.22 Cr | 0.2966 | 1.54 Cr | 19.31 Cr | 23.77 Cr | 7.35 Cr | 3.11 | 14.63 Cr | 0.0482 |
| 2023-03-31 | 115.35 Cr | 76.59 Cr | 38.76 Cr | 0.3360 | 0.72 Cr | 1.48 Cr | 11.77 Cr | 11.34 Cr | 4.79 | 18.99 Cr | 0.0983 |
| 2022-03-31 | 85.14 Cr | 51.54 Cr | 33.60 Cr | 0.3946 | 1.47 Cr | 1.99 Cr | 6.64 Cr | 5.22 Cr | 2.21 | 11.23 Cr | 0.0613 |
| 2021-03-31 | 71.22 Cr | 62.23 Cr | 8.98 Cr | 0.1261 | 1.36 Cr | 0.72 Cr | 6.14 Cr | 5.83 Cr | 2.46 | 10.39 Cr | 0.0818 |
| 2020-03-31 | 42.47 Cr | 40.54 Cr | 1.93 Cr | 0.0454 | 1.01 Cr | 1.21 Cr | -1.96 Cr | -1.88 Cr | -104.54 | 1.39 Cr | -0.0442 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1.40 Cr | 147.68 Cr | 66.84 Cr | 80.8390 Cr | 24.39 Cr | 22.99 Cr | 29.64 Cr | 50.71 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 54.0830 Cr |
| 2023-03-31 | 7.81 Cr | 129.58 Cr | 56.13 Cr | 73.4546 Cr | 22.92 Cr | 15.11 Cr | 22.22 Cr | 40.23 Cr | 0.00 Cr | 1.22 Cr | 0.00 Cr | 46.4763 Cr |
| 2022-03-31 | 0.02 Cr | 90.14 Cr | 28.18 Cr | 61.9637 Cr | 11.06 Cr | 11.04 Cr | 20.28 Cr | 38.85 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 22.0127 Cr |
| 2021-03-31 | 0.75 Cr | 86.47 Cr | 29.69 Cr | 56.7711 Cr | 15.79 Cr | 12.25 Cr | 15.44 Cr | 36.80 Cr | 0.89 Cr | 0.00 Cr | 0.00 Cr | 24.3088 Cr |
| 2020-03-31 | 8.19 Cr | 71.06 Cr | 20.12 Cr | 50.9454 Cr | 3.02 Cr | -5.17 Cr | 11.41 Cr | 35.18 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 17.0996 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 9.4848 Cr | -15.0536 Cr | -0.8454 Cr | -6.3634 Cr | -6.4134 Cr | 1.3960 Cr | -15.5782 Cr | 7.3479 Cr | 1.4654 Cr | 0.0000 Cr | -7.4231 Cr |
| 2023-03-31 | 4.9525 Cr | -7.4932 Cr | 10.1771 Cr | -3.2661 Cr | 7.6364 Cr | 7.8094 Cr | -6.7187 Cr | 11.7691 Cr | 11.8645 Cr | 0.0000 Cr | -1.9391 Cr |
| 2022-03-31 | 9.7283 Cr | -6.5442 Cr | -4.8148 Cr | 2.1871 Cr | -1.6307 Cr | 0.1730 Cr | -7.5412 Cr | 5.2163 Cr | -4.7266 Cr | 0.0000 Cr | -4.8372 Cr |
| 2021-03-31 | -13.6089 Cr | -5.3454 Cr | 12.2798 Cr | -19.7036 Cr | -6.6764 Cr | 1.8037 Cr | -6.0947 Cr | 5.8267 Cr | 12.3684 Cr | 0.0000 Cr | -4.0309 Cr |
| 2020-03-31 | -34.2680 Cr | 32.7748 Cr | 7.2713 Cr | -35.6968 Cr | 5.7669 Cr | 8.4801 Cr | -1.4288 Cr | -1.8834 Cr | -43.2403 Cr | 0.0000 Cr | -2.1292 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 33.19 Cr | 23.63 Cr | 9.56 Cr | 0.2881 | 1.41 Cr | 0.95 Cr | 0.40 | 3.24 Cr | 0.0286 |
| 2024-09-30 | 40.32 Cr | 27.76 Cr | 12.57 Cr | 0.3117 | 2.22 Cr | 2.62 Cr | 1.11 | 4.82 Cr | 0.0649 |
| 2024-06-30 | 33.29 Cr | 31.68 Cr | 1.61 Cr | 0.0484 | -0.23 Cr | -0.72 Cr | -0.31 | 1.37 Cr | -0.0217 |
| 2024-03-31 | 41.40 Cr | 34.89 Cr | 6.51 Cr | 0.1573 | 1.62 Cr | 1.46 Cr | 0.62 | 3.40 Cr | 0.0352 |
| 2023-12-31 | 28.44 Cr | 23.29 Cr | 5.15 Cr | 0.1811 | -3.35 Cr | -2.94 Cr | -1.24 | -1.10 Cr | -0.1035 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 1.31 Cr | 0.01 Cr | 1.32 Cr | 0.00 Cr | 27.47 Cr | 74.61 Cr | 55.53 Cr | 134.16 Cr | 51.41 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 1.40 Cr | 0.00 Cr | 0.00 Cr | 1.40 Cr | 0.00 Cr | 0.00 Cr | -80.84 Cr |
| 2024-03-31 | 1.40 Cr | 0.70 Cr | 1.40 Cr | 45.39 Cr | 29.64 Cr | 94.47 Cr | 50.71 Cr | 147.68 Cr | 66.84 Cr |
| 2023-12-31 | -7.86 Cr | 15.73 Cr | 7.86 Cr | 0.00 Cr | 0.00 Cr | 7.86 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 7.86 Cr | 0.00 Cr | 7.86 Cr | 39.83 Cr | 29.36 Cr | 90.95 Cr | 40.89 Cr | 134.87 Cr | 52.51 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | -0.72 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 1.46 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | -2.94 Cr | 2.54 Cr | 0.00 Cr | 0.00 Cr | 2.54 Cr | 10.41 Cr | 7.86 Cr | 0.00 Cr | 2.54 Cr |
| 2023-09-30 | 2.48 Cr | 2.48 Cr | 0.00 Cr | 0.00 Cr | 2.48 Cr | 7.86 Cr | 5.38 Cr | 0.00 Cr | 2.48 Cr |
| 2023-06-30 | 6.35 Cr | 2.43 Cr | 0.00 Cr | 0.00 Cr | 2.43 Cr | 10.24 Cr | 7.81 Cr | 0.00 Cr | 2.43 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2019-08-26 | August 26, 19 | 1:10 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,748.00 | ₹4,193,941,440,000.00 | ₹1,148,922.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,045.00 | ₹1,604,760,105,000.00 | ₹449,981.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,140.00 | ₹1,062,717,300,000.00 | ₹535,042.00 |
| Mankind Pharma Limited | MANKIND | ₹2,404.00 | ₹991,838,762,080.00 | ₹567,777.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,158.10 | ₹964,828,188,462.00 | ₹1,248,300.00 |
| Lupin Limited | LUPIN | ₹2,035.00 | ₹929,215,595,000.00 | ₹558,111.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹880.90 | ₹886,388,007,000.00 | ₹783,082.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,159.80 | ₹673,614,159,600.00 | ₹645,512.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,950.00 | ₹591,846,750,000.00 | ₹53,048.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,393.00 | ₹393,105,993,000.00 | ₹479,938.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,356.00 | ₹344,022,624,000.00 | ₹153,297.00 |
| Laurus Labs Limited | LAURUSLABS | ₹589.05 | ₹317,646,979,650.00 | ₹1,383,505.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,531.10 | ₹316,164,763,200.00 | ₹45,303.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,076.90 | ₹274,141,048,500.00 | ₹138,631.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,524.00 | ₹237,251,748,000.00 | ₹135,150.00 |
| Piramal Enterprises Limited | PEL | ₹1,012.10 | ₹228,206,283,800.00 | ₹661,159.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹7,993.00 | ₹199,825,000,000.00 | ₹14,627.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,228.30 | ₹199,572,955,700.00 | ₹413,280.00 |
| Eris Lifesciences Limited | ERIS | ₹1,459.00 | ₹198,693,915,000.00 | ₹113,370.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹896.55 | ₹176,228,557,650.00 | ₹93,847.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,363.00 | ₹158,616,053,700.00 | ₹41,048.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹810.20 | ₹145,114,922,000.00 | ₹453,167.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,860.00 | ₹141,381,762,000.00 | ₹62,202.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹863.00 | ₹137,459,503,000.00 | ₹128,164.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹441.95 | ₹107,192,320,800.00 | ₹1,886,979.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,045.00 | ₹83,743,973,000.00 | ₹5,996.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹773.00 | ₹70,060,561,260.00 | ₹487,812.00 |
| FDC Limited | FDC | ₹430.00 | ₹70,008,300,000.00 | ₹84,454.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹638.95 | ₹62,483,495,555.00 | ₹133,815.00 |
| Strides Pharma Science Limited | STAR | ₹639.30 | ₹58,919,614,110.00 | ₹149,838.00 |
| Innova Captab Limited | INNOVACAP | ₹849.50 | ₹48,612,578,035.00 | ₹198,796.00 |
| Hikal Limited | HIKAL | ₹385.35 | ₹47,514,040,350.00 | ₹199,111.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹141.31 | ₹45,858,203,820.00 | ₹337,923.00 |
| Sequent Scientific Limited | SEQUENT | ₹160.98 | ₹40,293,615,960.00 | ₹1,484,319.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹778.00 | ₹39,459,459,800.00 | ₹21,883.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹560.00 | ₹39,427,248,000.00 | ₹31,585.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹423.00 | ₹38,607,210,000.00 | ₹570,318.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹355.00 | ₹35,598,690,000.00 | ₹51,448.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,042.00 | ₹33,772,638,000.00 | ₹9,278.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹57.00 | ₹31,233,378,000.00 | ₹7,592,577.00 |
| Suven Life Sciences Limited | SUVEN | ₹142.01 | ₹30,968,688,740.00 | ₹870,137.00 |
| Alembic Limited | ALEMBICLTD | ₹98.80 | ₹25,370,061,501.00 | ₹279,135.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹502.50 | ₹23,259,467,243.00 | ₹75,590.00 |
| Indoco Remedies Limited | INDOCO | ₹240.00 | ₹22,139,496,000.00 | ₹38,062.00 |
Key Executives
Whole-Time Director of Quality
Mr. Vinayak Dinesh Dendukuri
Gender: male
Year Born: 1987
Executive Chairman
Ms. Shanmugam Hemalatha
Gender: female
Year Born: 1975
Company Secretary & Compliance Officer
Mr. A. Mohanachandran
Gender: male
Year Born:
Chief Executive Officer
Mr. Bansilal Mahaveer Chand Bafna
Gender: male
Year Born: 1961
Chief Financial Officer
Mr. Melagiri Sridhar
Gender: male
Year Born: 1968
FAQs about Bafna Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Mr. Bansilal Mahaveer Chand Bafna.
What is the current market price of the stock?
The current price is ₹72.00.
What is the 52-week price range?
The range is ₹69-104.8.
What is the market capitalization of the company?
The market capitalization is ₹170.33 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 39.70.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Bafna Pharmaceuticals Limited (ISIN: INE878I01022) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹170.33 crores and an average daily volume of 2,763 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.